An interventional study of DKutting LL balloon and Chocolate balloon in Femoral Artery Stenosis and Popliteal Artery Stenosis, sponsored by DK Medical Technology (Suzhou) Co., Ltd.. Completed at 14 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-02-20.
Sponsored by DK Medical Technology (Suzhou) Co., Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Constriction, Pathologic with a site in China — 37 open to participants now, 40 under way, 3 of them phase 3. Constriction, Pathologic · China.
Among the 81 studies in Constriction, Pathologic with a site in China, this one is the 24th largest by enrollment of the 56 interventional ones that give a count, is one of 7 that started in 2022, is one of 48 with no phase, and was the 37th registered.
457 studies on the registry are indexed under Constriction, Pathologic; 110 are open to participants now.
Browse Constriction, Pathologic studies →37 of the 81 studies in Constriction, Pathologic with a site in China are open now. Recruiting first, the newest first:
Xuanwu Hospital, Beijing · Sites in China
Ages 18–80
General Hospital of Shenyang Military Region · Sites in China
Ages 40+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–80
Xin Lou · Sites in China
Ages 18–90
The Second Hospital of Anhui Medical University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 67 Constriction, Pathologic studies recruiting now, 34 (51%) set no upper age limit and 14 (21%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 5 · Phase 4 1
First in 2008; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 188 is above the median of 72 across 296 interventional studies indexed under Constriction, Pathologic.
Median enrollment 145 across the 56 interventional studies, 400 across the 25 observational. Of the 20 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 81 have an industry lead sponsor. The 10 most frequent:
DK Medical Technology (Suzhou) Co., Ltd. is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
DK Medical Technology (Suzhou) Co., Ltd. has 3 studies filed under Constriction, Pathologic — fewer than ten, so there is no comparison to draw.
15 of the studies in Constriction, Pathologic with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07197970Phase 3Beijing Tiantan HospitalDrug- Eluting Stent for Symptomatic Intracranial Arterial Stenosis | 2027-05-15 |
| NCT07542938Xuanwu Hospital, BeijingMedeliver Intracranial Drug Coated Balloon Catheter for Symptomatic Intracranial Atherosclerotic Stenosis | 2026-11-30 |
| NCT07462546General Hospital of Shenyang Military RegionTranscranial Doppler for Internal Carotid Artery Stenting (TCD-ICAS) | 2026-11-30 |
| NCT06503692DK Medical Technology (Suzhou) Co., Ltd.Scoring Balloon and High Pressure Balloon in the Treatment of Arteriovenous Graft Stenosis | 2026-12 |
| NCT06539689FrontAce Scientific Co., LtdA Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries | 2026-12-04 |
Add all 15 to your calendar (.ics) → With an account.
Among the 81 studies in Constriction, Pathologic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Multicenter, Prospective, Randomized Controlled Trial to Evaluate the Efficacy and Safety of DKutting Balloon Versus Chocolate Balloon in the Treatment of Femoral and Popliteal Artery Stenosis
This is a prospective, multi-center, randomized controlled, open-label, noninferior study to evaluate achievement of optimal PTA dilatation. A total of 188 patients will be enrolled from 14 sites in China. All patients enrolled will be assigned to the test group (DKutting LL balloon, n=94) and the control group (Chocolate balloon, n=94) with randomized allocation ratio of 1:1.
Primary endpoint is percentage of PTA cases in which \<30% diameter stenosis without a flow limiting dissection is achieved. A 30-day after procedure follow-up will be conducted for all 188 patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DKutting LL Scoring Balloon, DK Medtech Co Ltd
Device: DKutting LL balloon
Chocolate Balloon, TriReme Medical LLC
Device: Chocolate balloon
After pre-dilation balloon is used (if any), DKutting LL balloon is used as final dilatation balloon before Stent implantation or Drug Coated Balloon deployment
After pre-dilation balloon is used (if any), Chocolate balloon is used as final dilatation balloon before Stent implantation or Drug Coated Balloon deployment
Achievement of Optimal PTA in Percent
Percentage of PTA cases in which \<30% diameter stenosis without a flow limiting dissection (NHLBI grading: D-F). Residual stenosis in percent and dissection NHLBI grading are accessed by independent core-lab with Medis Suite XA based on in-procedure QCA angiography. \[0-100%, higher the better\]
Time frame: 1 day
Device Success Rate in Percent
Device Success defined as successful delivery to the target lesion, deployment without balloon rupture, and retrieval after procedure, as qualitatively accessed by physician. \[0-100%, higher the better\]
Time frame: 1 day
Numerical Acute Lumen Gain in mm
In-lesion acute lumen gain defined as minimal lumen diameter (MLD) in lumen after dilatation by either arm device minus baseline MLD, as accessed by independent core-lab with Medis Suite XA based on in-procedure QCA angiography. \[0-3mm, higher the better\]
Time frame: 1 day
Technical Success Rate in percent
Percentage of target Lesion achieved \<30% diameter stenosis without a flow limiting dissection (NHLBI grading: D-F) and No Adverse Event happened in hospital. \[0-100%, higher the better\]
Time frame: 0-7 days
Freedom from clinical-driven TLR rate in percent
Freedom from clinical-driven target lesion revascularization 1 month post procedure \[0-100%, higher the better\]
Time frame: 30+/-7 Days post procedure
Rutherford Grading Reduction in percent
Percentage of both groups' patent number, whose Rutherford Grading \[0-6, lower is reduced by at least 1 grade post procedure, compared with pre-procedure grade. \[0-100%, higher the better\]
Time frame: 30+/-7 Days post procedure
Freedom from Amputation above ankle rate in percent
Percentage of both groups' patient number who is free from Amputation above ankle 1 month post procedure. \[0-100%, higher the better\]
Time frame: 30+/-7 Days post procedure
Numerical Ankle Brachial Index
Record of both groups' patient's Ankle Brachial Index (ABI) pre/post procedure by Doppler ultrasonic stethoscope. \[ABI≤0.9: confirmed peripheral artery disease; ABI≥0.97: normal people\]
Time frame: 0-7days
Ran from Dec 2022 to primary completion in Jan 2024, 12 months.
Of 43 industry-sponsored interventional studies with no phase under Constriction, Pathologic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 58. This study's 12 months is below that.
Counting every sponsor, half of 133 studies reached it within 36 months; a quarter within 18 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
DK Medical Technology (Suzhou) Co., Ltd.